Larry B. Goldstein

Larry B. Goldstein, MD, is a Professor and Chair of the Department of Neurology at the University of Kentucky, as well as the Associate Dean for Clinical Research. His academic appointments reflect his leadership in neurology, clinical research, and departmental administration. He is affiliated with the Equity Advisory Council and leads the Center for Advanced Translational Stroke Science (CATSS). His research focuses on stroke mechanisms, biomarkers, and vascular cognitive impairment, with particular attention to amyloid angiopathy, stroke recurrence, and disparities in care. He has contributed to major clinical guidelines and position statements, including the 2024 AHA/ASA Stroke Prevention Guidelines. Dr. Goldstein’s work spans translational research, clinical trials, and public health initiatives, aiming to enhance stroke prevention, treatment, and patient outcomes. He is a Fellow of the American Academy of Neurology (FAAN), American Neurological Association (FANA), and American Heart Association (FAHA).

His research interests emphasize neuroimaging biomarkers, stroke epidemiology, and the interplay between systemic conditions (e.g., diabetes) and cerebrovascular disease. Key projects include studies on amylin’s role in cerebral microvascular dysfunction and its implications for Alzheimer’s disease. He also investigates disparities in stroke care, including rural-urban differences and socioeconomic factors. Dr. Goldstein’s multidisciplinary approach integrates clinical practice, basic science, and policy to address unmet needs in neurology.

• Labs/Initiatives: Director of the Center for Advanced Translational Stroke Science (CATSS) and Kentucky Neuroscience Institute.
• Grants/Awards: Recognized through FAAN, FANA, and FAHA fellowships, reflecting his clinical and research excellence.
• Education: Leads neurology residency and fellowship programs, emphasizing translational research and clinical innovation.

His publications highlight contributions to understanding stroke pathophysiology, improving stroke systems of care, and advancing neurotherapeutics. Dr. Goldstein’s leadership in academic medicine addresses workforce wellbeing and healthcare economics, as seen in studies on physician burnout and funding models for neurology departments.